Trial Profile
Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Thyrotropin alfa
- Indications Thyroid cancer
- Focus Adverse reactions
- 30 Jun 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 30 Jun 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 25 Jan 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.